Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi
Tahata S, Singh SV, Lin Y, Hahm ER, Beumer JH, Christner SM, Rao UN, Sander C, Tarhini AA, Tawbi H, Ferris LK, Wilson M, Rose A, Dietz CM, Hughes E, Fahey JW, Leachman SA, Cassidy PB, Butterfield LH, Zarour HM, Kirkwood JM
Cancer prevention research (Philadelphia, Pa.) · 67 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institutes of Health
- Gobierno
- National Cancer Institute
- Gobierno
- NCI NIH HHS
- Universidad u hospital
- Immunologic Monitoring and Cellular Products Laboratory
- Gobierno
- NIH
- Subvenciones
- National Cancer Institute (R21 CA161951); National Cancer Institute (P30 CA 047904); National Institutes of Health (R21CA161951)
Según 5 financiadores declarados.
Publicación
- Publicado
- 2018-04-24 · Cancer Prev Res (Phila) · vol. 11 · número 7 · págs. 429–438
- Editorial
- American Association for Cancer Research
- Citado
- 87 citas · más que el 93% de estudios similares · 3.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 49 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Genomics, phytochemicals, and oxidative stress · Bioactive Compounds and Antitumor Agents · Immune Cell Function and Interaction
- Palabras clave
- Sulforaphane, Medicine, Melanoma, Toxicity, Pharmacology, Gastroenterology, Internal medicine, Cancer research
- MeSH
- skin, humans, brassica, melanoma, nevus, skin neoplasms, isothiocyanates, sulfoxides, plant extracts, capsules, biopsy, treatment outcome, administration, oral, feasibility studies, tissue distribution, pregnancy, adult, aged, middle aged, female, male, young adult, biomarkers, tumor
21 autores
- Shawn Tahata🇺🇸UPMC Hillman Cancer Center
- Shivendra Vikram Singh🇺🇸University of Pittsburgh; UPMC Hillman Cancer Center
- Yan Lin🇺🇸UPMC Hillman Cancer Center
- Eun‐Ryeong Hahm🇺🇸University of Pittsburgh
- Jan Hendrik Beumer🇺🇸University of Pittsburgh; UPMC Hillman Cancer Center
- Susan M. Christner🇺🇸UPMC Hillman Cancer Center
- Uma N. M. Rao🇺🇸UPMC Hillman Cancer Center
- Cindy Sander🇺🇸UPMC Hillman Cancer Center
- Ahmad A. Tarhini🇺🇸Cleveland Clinic
- Hussein A. Tawbi🇺🇸The University of Texas MD Anderson Cancer Center
- Laura Korb Ferris🇺🇸University of Pittsburgh
- Melissa Ann Wilson🇺🇸UPMC Hillman Cancer Center
- Amy E. Rose🇺🇸UPMC Hillman Cancer Center
- Catherine M. Dietz
- Ellen L Hughes
- Jed W. Fahey🇺🇸Johns Hopkins University; Johns Hopkins Medicine
- Sancy Ann Leachman🇺🇸Oregon Health & Science University
- Pamela B. Cassidy🇺🇸Oregon Health & Science University
- Lisa Helene Butterfield🇺🇸University of Pittsburgh; UPMC Hillman Cancer Center
- Hassane M. Zarour🇺🇸University of Pittsburgh; UPMC Hillman Cancer Center
- John M. Kirkwood🇺🇸 · autor de correspondenciaUniversity of Pittsburgh; UPMC Hillman Cancer Center
Resumen
El texto original del estudio, en el idioma en que se publicó.
Broccoli sprout extract containing sulforaphane (BSE-SFN) has been shown to inhibit ultraviolet radiation-induced damage and tumor progression in skin. This study evaluated the toxicity and potential effects of oral BSE-SFN at three dosages. Seventeen patients who each had at least 2 atypical nevi and a prior history of melanoma were randomly allocated to 50, 100, or 200 μmol oral BSE-SFN daily for 28 days. Atypical nevi were photographed on days 1 and 28, and plasma and nevus samples were taken on days 1, 2, and 28. Endpoints assessed were safety, plasma and skin sulforaphane levels, gross and histologic changes, IHC for phospho-STAT3(Y705), Ki-67, Bcl-2, HMOX1, and TUNEL, plasma cytokine levels, and tissue proteomics. All 17 patients completed 28 days with no dose-limiting toxicities. Plasma sulforaphane levels pooled for days 1, 2, and 28 showed median postadministration increases of 120 ng/mL for 50 μmol, 206 ng/mL for 100 μmol, and 655 ng/mL for 200 μmol. Median skin sulforaphane levels on day 28 were 0.0, 3.1, and 34.1 ng/g for 50, 100, and 200 μmol, respectively. Plasma levels of proinflammatory cytokines decreased from day 1 to 28. The tumor suppressor decorin was increased from day 1 to 28. Oral BSE-SFN is well tolerated at daily doses up to 200 μmol and achieves dose-dependent levels in plasma and skin. A larger efficacy evaluation of 200 μmol daily for longer intervals is now reasonable to better characterize clinical and biological effects of BSE-SFN as chemoprevention for melanoma. Cancer Prev Res; 11(7); 429-38. ©2018 AACR.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.